CRVO Stock Analysis: Buy, Sell, or Hold?
CRVO - CervoMed Inc. Common Stock
$2.80
0.20 (7.69%)
▲
5d:
+9.37%
30d:
-21.57%
90d:
-24.32%
BUY
MODERATE Confidence
Analysis Updated: Aug 4, 2026 12:00 AM ET
Earnings: Aug 14, 2026
8d
Get Alerted When CRVO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CRVO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: CRVO shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: CRVO is currently trading at $2.80, which is considered slightly low relative to its 30-day fair value range of $2.66 to $3.44.
Technical Outlook: Technically, CRVO is in a strong downtrend. Immediate support is located at $2.43, while resistance sits at $2.94. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: CRVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.20 (+585.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CRVO is in a strong downtrend. Immediate support is located at $2.43, while resistance sits at $2.94. The stock is showing strong short-term momentum, up 7.7% recently.
Market Sentiment: CRVO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.20 (+585.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$2.66 -
$3.44
Company Quality Score
40/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+7.7%)
- BULLISH: Trading 585.7% below Wall St target ($19.20)
Trading Range Analysis
30-Day Trading Range
$2.66 -
$3.44
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$2.43
Resistance Level
$2.94
Current Trend
Strong Downtrend
Technical data as of
Aug 4, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.12
Wall Street Target
$19.20
(+585.7%)
Revenue Growth (YoY)
-99.6%
Share & Embed Analysis
Last updated: August 04, 2026 7:16 PM ET
Data refreshes hourly during market hours. Next update: 8:16 PM
Data refreshes hourly during market hours. Next update: 8:16 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CRVO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1080 | 57 HOLD |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 45 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$52 | 53 HOLD |
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
20 analysts |
$127 | 56 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
